{
  "corpus": "RareDis-Feasibility",
  "description": "20 synthetic documents for rare disease clinical trial feasibility evaluation covering patient funnel, local guidelines, investigator presence, and patient populations across 20 countries",
  "version": "1.0",
  "documents": [
    {
      "doc_id": "01_fabry_disease_germany.pdf",
      "disease": "Fabry Disease",
      "country": "Germany",
      "study_design": {
        "phase": "3",
        "design_type": "parallel",
        "blinding": "double-blind",
        "randomization_ratio": "1:1",
        "sample_size": 120,
        "actual_enrollment": 112,
        "duration_months": 18,
        "treatment_arms": [
          {
            "name": "Pegunigalsidase alfa",
            "n": 56,
            "dose": "1 mg/kg",
            "frequency": "every 2 weeks",
            "route": "IV"
          },
          {
            "name": "Agalsidase beta",
            "n": 56,
            "dose": "1 mg/kg",
            "frequency": "every 2 weeks",
            "route": "IV"
          }
        ],
        "control_type": "active_comparator",
        "setting": "multi-centre",
        "sites_total": 28,
        "countries_total": 12
      },
      "eligibility_inclusion": [
        {
          "text": "Age 18 to 65 years",
          "category": "age"
        },
        {
          "text": "Confirmed Fabry disease by alpha-galactosidase A enzyme assay or documented pathogenic GLA gene variant",
          "category": "disease_definition"
        },
        {
          "text": "eGFR >= 40 mL/min/1.73m2 by CKD-EPI equation",
          "category": "lab_value"
        },
        {
          "text": "UPCR < 1.0 g/g",
          "category": "lab_value"
        },
        {
          "text": "Stable dose of ACEi or ARB for at least 90 days prior to screening",
          "category": "prior_therapy"
        },
        {
          "text": "If currently on ERT, stable dose for at least 12 months",
          "category": "prior_therapy"
        }
      ],
      "eligibility_exclusion": [
        {
          "text": "Dialysis or prior renal transplant",
          "category": "organ_function"
        },
        {
          "text": "History of severe anaphylactic reaction to ERT",
          "category": "medical_history"
        },
        {
          "text": "Uncontrolled hypertension (systolic BP > 160 mmHg or diastolic > 100 mmHg)",
          "category": "vital_signs"
        },
        {
          "text": "Pregnancy or breastfeeding",
          "category": "pregnancy"
        },
        {
          "text": "Participation in another interventional trial within 30 days",
          "category": "other_trial"
        },
        {
          "text": "Clinically significant cardiac arrhythmia requiring antiarrhythmic therapy",
          "category": "cardiac"
        }
      ],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 40,000",
          "geography": "Germany",
          "source": "population-based screening studies"
        },
        {
          "data_type": "incidence",
          "value": "1 in 80,000 live births",
          "geography": "worldwide"
        }
      ],
      "screening_flow": {
        "screened": 198,
        "screen_failures": 86,
        "randomized": 112,
        "treated": 110,
        "completed": 101,
        "discontinued": 9,
        "screen_failure_rate": 43.4,
        "screen_fail_reasons": [
          {
            "reason": "eGFR below threshold",
            "count": 32,
            "percentage": 37.2
          },
          {
            "reason": "Withdrawal of consent",
            "count": 18,
            "percentage": 20.9
          },
          {
            "reason": "Prior renal transplant",
            "count": 14,
            "percentage": 16.3
          },
          {
            "reason": "Unstable ACEi/ARB dose",
            "count": 12,
            "percentage": 14.0
          },
          {
            "reason": "Other reasons",
            "count": 10,
            "percentage": 11.6
          }
        ],
        "reasons_can_overlap": true
      },
      "operational_burden": {
        "invasive_procedures": [
          {
            "name": "renal biopsy",
            "timing": [
              "screening"
            ],
            "purpose": "diagnosis_confirmation",
            "is_eligibility_requirement": true
          },
          {
            "name": "IV infusion",
            "timing": [
              "every 2 weeks"
            ],
            "purpose": "treatment_administration"
          }
        ],
        "visit_schedule": {
          "total_visits": 22,
          "frequency": "every 2 weeks for infusion, every 3 months for assessment"
        },
        "central_lab_required": true,
        "central_lab_analytes": [
          "alpha-galactosidase A activity",
          "plasma Gb3",
          "lyso-Gb3",
          "eGFR",
          "proteinuria"
        ],
        "background_therapy": [
          {
            "therapy_class": "ACEi/ARB",
            "requirement_type": "required_stable",
            "stable_duration_days": 90
          }
        ],
        "hard_gates": [
          "confirmed Fabry genotype",
          "renal biopsy",
          "eGFR threshold"
        ]
      },
      "endpoints": [
        {
          "type": "primary",
          "name": "Annualized rate of change in eGFR",
          "measure": "eGFR (CKD-EPI)",
          "timepoint": "18 months"
        },
        {
          "type": "secondary",
          "name": "Change in plasma lyso-Gb3",
          "timepoint": "18 months"
        },
        {
          "type": "secondary",
          "name": "Change in left ventricular mass index by cardiac MRI",
          "timepoint": "18 months"
        },
        {
          "type": "safety",
          "name": "Infusion-associated reactions",
          "timepoint": "18 months"
        }
      ],
      "sites_and_investigators": {
        "total_sites": 28,
        "total_countries": 12,
        "countries": [
          "Germany",
          "France",
          "United Kingdom",
          "Italy",
          "Spain",
          "Netherlands",
          "United States",
          "Canada",
          "Brazil",
          "Japan",
          "Australia",
          "South Korea"
        ],
        "investigator_requirements": "Board-certified nephrologist or metabolic disease specialist with >= 3 years Fabry disease experience"
      },
      "local_guidelines": {
        "guideline_name": "German Society for Nephrology Fabry Disease Guidelines 2023",
        "key_recommendations": [
          "ERT initiation recommended when eGFR < 90 or proteinuria > 300 mg/day",
          "Genetic confirmation mandatory before ERT start",
          "Monitoring every 6 months with cardiac MRI annually"
        ],
        "impact_on_feasibility": "Guideline-mandated genetic testing aligns with trial eligibility; existing monitoring infrastructure supports trial visit schedule"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 1200,
        "estimated_eligible_patients": 340,
        "registry_name": "Fabry Registry (Sanofi Genzyme)",
        "registry_size": 4800,
        "diagnostic_delay_years": 13.7,
        "referral_centres": 18,
        "geographic_distribution": "Concentrated in university hospitals in Berlin, Munich, Hamburg, Cologne"
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 13.7,
          "diagnostic_tests_required": [
            "alpha-galactosidase A enzyme assay",
            "GLA gene sequencing"
          ],
          "specialist_type": "metabolic disease specialist or nephrologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Enzyme replacement therapy (ERT) with agalsidase beta or alfa",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "ERT (agalsidase beta 1 mg/kg IV every 2 weeks)"
            },
            {
              "line": 2,
              "therapy": "Oral chaperone therapy (migalastat) for amenable mutations"
            }
          ]
        },
        "trial_phases": [
          {
            "phase": "screening",
            "duration": "4 weeks",
            "visits": 3,
            "procedures": [
              "blood draw",
              "ECG",
              "renal biopsy"
            ]
          },
          {
            "phase": "treatment",
            "duration": "18 months",
            "visits": 22,
            "visit_frequency": "every 2 weeks"
          }
        ],
        "participation_barriers": [
          "renal biopsy requirement",
          "biweekly IV infusion schedule",
          "travel to specialist centre"
        ],
        "country": "Germany",
        "region": "Europe"
      }
    },
    {
      "doc_id": "02_huntington_disease_uk.pdf",
      "disease": "Huntington Disease",
      "country": "United Kingdom",
      "study_design": null,
      "eligibility_inclusion": [],
      "eligibility_exclusion": [],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "12.3 per 100,000",
          "geography": "United Kingdom"
        },
        {
          "data_type": "incidence",
          "value": "0.7 per 100,000 person-years",
          "geography": "United Kingdom"
        },
        {
          "data_type": "prevalence",
          "value": "14.6 per 100,000",
          "geography": "Scotland"
        },
        {
          "data_type": "prevalence",
          "value": "13.1 per 100,000",
          "geography": "Wales"
        }
      ],
      "screening_flow": {
        "screen_failure_rate_avg": 38,
        "screening_to_randomization_ratio": "2.5:1 to 3.5:1",
        "dropout_rate": "12-18% in 12-month trials"
      },
      "operational_burden": {
        "invasive_procedures": [
          {
            "name": "lumbar puncture",
            "timing": [
              "as per protocol"
            ],
            "purpose": "biomarker_collection",
            "note": "trials requiring lumbar puncture report 20-25% dropout"
          }
        ],
        "visit_schedule": {
          "frequency": "UHDRS-TMS every 6 months, cognitive assessment annually"
        }
      },
      "endpoints": [],
      "sites_and_investigators": {
        "total_sites": 16,
        "total_countries": 1,
        "countries": [
          "United Kingdom"
        ],
        "investigator_count": 42,
        "investigator_requirements": "at least 3 completed HD trials as PI or sub-investigator"
      },
      "local_guidelines": {
        "guideline_name": "British Neurological Association and Huntington's Disease Association UK Clinical Practice Guidelines 2024",
        "key_recommendations": [
          "Tetrabenazine first-line for chorea",
          "SSRIs first-line for depression",
          "Multidisciplinary team essential",
          "Volumetric MRI for research participants"
        ],
        "impact_on_feasibility": "Established specialist centre network with 16 sites and > 50 patient panel per site supports trial infrastructure"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 8000,
        "estimated_eligible_early_moderate": 4200,
        "pre_manifest_carriers": 2400,
        "registry_name": "ENROLL-HD / EHDN Registry",
        "registry_size": 3200,
        "diagnostic_delay_years": 3.2,
        "referral_centres": 16,
        "geographic_distribution": "England 10, Scotland 3, Wales 2, Northern Ireland 1"
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 5.0,
          "diagnostic_tests_required": [
            "genetic testing for HTT CAG repeat expansion",
            "neurological examination"
          ],
          "specialist_type": "neurologist or clinical geneticist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Symptomatic management (tetrabenazine for chorea, SSRIs for depression)",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Tetrabenazine for chorea"
            },
            {
              "line": 2,
              "therapy": "Deutetrabenazine or valbenazine"
            }
          ]
        },
        "participation_barriers": [
          "progressive cognitive decline limits consent capacity",
          "limited specialist centres",
          "genetic testing reluctance"
        ],
        "country": "United Kingdom",
        "region": "Europe"
      }
    },
    {
      "doc_id": "03_pah_france.pdf",
      "disease": "Pulmonary Arterial Hypertension",
      "country": "France",
      "study_design": {
        "phase": "2/3",
        "design_type": "parallel",
        "blinding": "double-blind",
        "randomization_ratio": "2:1",
        "sample_size": null,
        "actual_enrollment": 224,
        "duration_months": 24,
        "treatment_arms": [
          {
            "name": "Selexipag + ambrisentan + tadalafil",
            "n": 150,
            "dose": "up to 1600 mcg twice daily",
            "frequency": "twice daily",
            "route": "oral"
          },
          {
            "name": "Placebo + ambrisentan + tadalafil",
            "n": 74
          }
        ],
        "control_type": "placebo",
        "setting": "multi-centre",
        "sites_total": 35,
        "countries_total": 8
      },
      "eligibility_inclusion": [
        {
          "text": "Age 18 to 75 years",
          "category": "age"
        },
        {
          "text": "PAH confirmed by right heart catheterization: mPAP >= 25 mmHg, PCWP <= 15 mmHg, PVR > 3 Wood units",
          "category": "disease_definition"
        },
        {
          "text": "WHO functional class II or III",
          "category": "disease_severity"
        },
        {
          "text": "6MWD >= 150 meters and <= 500 meters",
          "category": "functional_status"
        },
        {
          "text": "Treatment-naive (no prior PAH-specific therapy)",
          "category": "prior_therapy"
        },
        {
          "text": "No significant left heart disease (LVEF > 50%)",
          "category": "organ_function"
        }
      ],
      "eligibility_exclusion": [
        {
          "text": "PAH associated with portal hypertension, HIV infection, or congenital heart disease with Eisenmenger physiology",
          "category": "disease_definition"
        },
        {
          "text": "Significant obstructive lung disease (FEV1 < 60% predicted)",
          "category": "organ_function"
        },
        {
          "text": "Severe hepatic impairment (Child-Pugh class C)",
          "category": "organ_function"
        },
        {
          "text": "Systolic blood pressure < 90 mmHg at screening",
          "category": "vital_signs"
        },
        {
          "text": "Recent pulmonary embolism within 12 months",
          "category": "medical_history"
        },
        {
          "text": "Planned or listed for lung transplantation",
          "category": "medical_history"
        }
      ],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "15 per million adults",
          "geography": "France",
          "source": "French National PAH Registry"
        },
        {
          "data_type": "incidence",
          "value": "2.4 per million per year",
          "geography": "France"
        }
      ],
      "screening_flow": {
        "screened": 312,
        "screen_failures": 88,
        "randomized": 224,
        "treated": 218,
        "completed": 189,
        "discontinued": 35,
        "screen_failure_rate": 28.2,
        "screen_fail_reasons": [
          {
            "reason": "Hemodynamic criteria not met at right heart catheterization",
            "count": 31,
            "percentage": 35.2
          },
          {
            "reason": "WHO functional class I or IV",
            "count": 19,
            "percentage": 21.6
          },
          {
            "reason": "Concomitant significant left heart disease",
            "count": 15,
            "percentage": 17.0
          },
          {
            "reason": "Withdrawal of consent",
            "count": 12,
            "percentage": 13.6
          },
          {
            "reason": "6MWD outside range",
            "count": 11,
            "percentage": 12.5
          }
        ]
      },
      "operational_burden": {
        "invasive_procedures": [
          {
            "name": "right heart catheterization",
            "timing": [
              "screening",
              "Week 24"
            ],
            "purpose": "diagnosis_confirmation and efficacy_assessment",
            "is_eligibility_requirement": true
          }
        ],
        "visit_schedule": {
          "total_visits": 16,
          "frequency": "variable intervals over 24 months"
        },
        "central_lab_required": true,
        "central_lab_analytes": [
          "NT-proBNP",
          "liver function panel",
          "complete blood count",
          "selexipag metabolite levels"
        ],
        "background_therapy": [
          {
            "therapy_class": "ambrisentan",
            "requirement_type": "required",
            "dose": "10 mg daily"
          },
          {
            "therapy_class": "tadalafil",
            "requirement_type": "required",
            "dose": "40 mg daily"
          }
        ],
        "hard_gates": [
          "right heart catheterization",
          "hemodynamic criteria",
          "treatment-naive status"
        ]
      },
      "endpoints": [
        {
          "type": "primary",
          "name": "Time to first morbidity/mortality event",
          "timepoint": "24 months"
        },
        {
          "type": "secondary",
          "name": "Change in 6MWD",
          "timepoint": "Week 24"
        },
        {
          "type": "secondary",
          "name": "Change in PVR by right heart catheterization",
          "timepoint": "Week 24"
        },
        {
          "type": "secondary",
          "name": "Change in NT-proBNP",
          "timepoint": "24 months"
        },
        {
          "type": "safety",
          "name": "Adverse events, liver function tests, systemic blood pressure",
          "timepoint": "24 months"
        }
      ],
      "sites_and_investigators": {
        "total_sites": 35,
        "total_countries": 8,
        "countries": [
          "France",
          "Germany",
          "United Kingdom",
          "Italy",
          "Spain",
          "United States",
          "Canada",
          "Australia"
        ],
        "investigator_requirements": "pulmonary hypertension board certification, catheterization laboratory access, patient panel >= 20 active PAH patients"
      },
      "local_guidelines": {
        "guideline_name": "Société de Pneumologie de Langue Française guidelines 2022",
        "key_recommendations": [
          "ESC/ERS 4-strata risk stratification",
          "Upfront dual or triple combination therapy for intermediate/high risk",
          "Right heart catheterization mandatory for diagnosis",
          "RHC at 3-6 month intervals for treatment response"
        ],
        "impact_on_feasibility": "National PAH network of 26 expert centres coordinated by Hôpital Bicêtre enables efficient recruitment"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 2500,
        "estimated_treatment_naive": 600,
        "estimated_eligible_patients": 320,
        "registry_name": "French National PAH Registry (Hôpital Bicêtre)",
        "registry_size": 2500,
        "referral_centres": 26
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 2.5,
          "diagnostic_tests_required": [
            "right heart catheterization",
            "echocardiography",
            "6-minute walk test"
          ],
          "specialist_type": "pulmonologist or cardiologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Endothelin receptor antagonists + PDE5 inhibitors (dual combination)",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "ERA + PDE5i dual combination"
            },
            {
              "line": 2,
              "therapy": "Addition of prostacyclin pathway agent"
            }
          ]
        },
        "trial_phases": [
          {
            "phase": "screening",
            "duration": "4 weeks",
            "visits": 3,
            "procedures": [
              "RHC",
              "6MWT",
              "blood draw"
            ]
          },
          {
            "phase": "treatment",
            "duration": "16 weeks",
            "visits": 8,
            "visit_frequency": "every 2 weeks"
          }
        ],
        "participation_barriers": [
          "right heart catheterization requirement",
          "multiple background therapies required stable"
        ],
        "country": "France",
        "region": "Europe"
      }
    },
    {
      "doc_id": "04_wilson_disease_japan.pdf",
      "disease": "Wilson Disease",
      "country": "Japan",
      "study_design": null,
      "eligibility_inclusion": [],
      "eligibility_exclusion": [],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 30,000",
          "geography": "Japan",
          "source": "Ministry of Health nationwide survey"
        },
        {
          "data_type": "incidence",
          "value": "1 in 35,000 live births",
          "geography": "Japan"
        }
      ],
      "screening_flow": {
        "screen_failure_rate_avg": 35,
        "screening_to_randomization_ratio": "2.8:1"
      },
      "operational_burden": null,
      "endpoints": [],
      "sites_and_investigators": {
        "total_sites": 23,
        "total_countries": 1,
        "countries": [
          "Japan"
        ],
        "investigator_count": 38,
        "investigator_requirements": "15 investigators with previous PI experience"
      },
      "local_guidelines": {
        "guideline_name": "Japan Society of Hepatology Wilson Disease Guidelines 2024",
        "key_recommendations": [
          "D-penicillamine first-line chelation",
          "Trientine alternative for D-penicillamine intolerance",
          "Zinc acetate for maintenance",
          "Leipzig scoring system for diagnosis",
          "Monitoring every 3 months on chelation"
        ],
        "impact_on_feasibility": "Wilson disease designated as Nanbyo No. 171, providing subsidy program access; 23 expert centres with established monitoring infrastructure"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 4200,
        "registry_name": "Japanese Wilson Disease Patient Registry",
        "registry_size": 2100,
        "stable_chelation": 1400,
        "neurological_involvement": 680,
        "estimated_eligible_patients": 480,
        "diagnostic_delay_years": 4.8,
        "referral_centres": 23
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 3.0,
          "diagnostic_tests_required": [
            "serum ceruloplasmin",
            "24-hour urine copper",
            "slit-lamp examination",
            "ATP7B gene sequencing"
          ],
          "specialist_type": "hepatologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Chelation therapy with D-penicillamine or trientine",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "D-penicillamine"
            },
            {
              "line": 2,
              "therapy": "Trientine or zinc acetate"
            }
          ]
        },
        "participation_barriers": [
          "rare disease with limited patient pool",
          "liver biopsy may be required",
          "copper monitoring complexity"
        ],
        "country": "Japan",
        "region": "Asia-Pacific"
      }
    },
    {
      "doc_id": "05_hae_usa.pdf",
      "disease": "Hereditary Angioedema",
      "country": "United States",
      "study_design": {
        "phase": "3",
        "design_type": "parallel",
        "blinding": "double-blind",
        "randomization_ratio": "2:1",
        "sample_size": null,
        "actual_enrollment": 180,
        "duration_months": 6,
        "treatment_arms": [
          {
            "name": "Donidalorsen",
            "n": 120,
            "dose": "80 mg",
            "frequency": "every 4 weeks",
            "route": "subcutaneous"
          },
          {
            "name": "Placebo",
            "n": 60
          }
        ],
        "control_type": "placebo",
        "setting": "multi-centre",
        "sites_total": 42,
        "countries_total": 6
      },
      "eligibility_inclusion": [
        {
          "text": "Age 12 to 75 years",
          "category": "age"
        },
        {
          "text": "Documented diagnosis of HAE type I or II: low C4, C1-INH functional activity below 50%",
          "category": "disease_definition"
        },
        {
          "text": "At least 3 investigator-confirmed HAE attacks per month during 3-month run-in",
          "category": "disease_severity"
        },
        {
          "text": "Stable prophylactic therapy or no prophylactic therapy for at least 3 months",
          "category": "prior_therapy"
        },
        {
          "text": "Access to and ability to use acute rescue medication",
          "category": "concomitant_therapy"
        }
      ],
      "eligibility_exclusion": [
        {
          "text": "HAE with normal C1-INH (formerly HAE type III)",
          "category": "disease_definition"
        },
        {
          "text": "Acquired angioedema (AAE)",
          "category": "disease_definition"
        },
        {
          "text": "Current use of long-term systemic corticosteroids > 10 mg prednisone daily",
          "category": "concomitant_therapy"
        },
        {
          "text": "Use of attenuated androgens within 3 months",
          "category": "washout"
        },
        {
          "text": "Severe hepatic impairment (ALT or AST > 3x ULN)",
          "category": "organ_function"
        },
        {
          "text": "History of thrombotic events within 12 months",
          "category": "medical_history"
        },
        {
          "text": "Pregnant or breastfeeding",
          "category": "pregnancy"
        }
      ],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 50,000",
          "geography": "United States",
          "source": "US HAEA registry"
        }
      ],
      "screening_flow": {
        "screened": 267,
        "screen_failures": 87,
        "randomized": 180,
        "treated": 176,
        "completed": 165,
        "discontinued": 15,
        "screen_failure_rate": 32.6,
        "screen_fail_reasons": [
          {
            "reason": "Fewer than 3 attacks per month during run-in",
            "count": 38,
            "percentage": 43.7
          },
          {
            "reason": "C1-INH functional activity within normal range",
            "count": 16,
            "percentage": 18.4
          },
          {
            "reason": "Unstable prophylactic therapy",
            "count": 14,
            "percentage": 16.1
          },
          {
            "reason": "Withdrawal of consent",
            "count": 9,
            "percentage": 10.3
          },
          {
            "reason": "Other reasons",
            "count": 10,
            "percentage": 11.5
          }
        ],
        "reasons_can_overlap": true
      },
      "operational_burden": {
        "visit_schedule": {
          "total_visits": 12,
          "frequency": "Weeks 0,2,4,8,12,16,20,24,28,32"
        },
        "central_lab_required": true,
        "central_lab_analytes": [
          "C4 levels",
          "C1-INH functional and antigenic levels",
          "prekallikrein levels",
          "aPTT",
          "liver function panel",
          "CBC with platelets"
        ],
        "hard_gates": [
          "attack frequency threshold",
          "complement testing confirmation"
        ]
      },
      "endpoints": [
        {
          "type": "primary",
          "name": "Monthly rate of investigator-confirmed HAE attacks",
          "timepoint": "6 months"
        },
        {
          "type": "secondary",
          "name": "Proportion achieving zero attacks",
          "timepoint": "6 months"
        },
        {
          "type": "secondary",
          "name": "Time to first HAE attack"
        },
        {
          "type": "secondary",
          "name": "AE-QoL change from baseline",
          "timepoint": "6 months"
        },
        {
          "type": "safety",
          "name": "Injection site reactions, liver function, coagulation, platelets",
          "timepoint": "6 months"
        }
      ],
      "sites_and_investigators": {
        "total_sites": 42,
        "total_countries": 6,
        "countries": [
          "United States",
          "Canada",
          "Germany",
          "France",
          "United Kingdom",
          "Australia"
        ],
        "investigator_requirements": "at least 15 active HAE patients and allergist/immunologist with HAE trial experience",
        "country_enrollment": [
          {
            "country": "United States",
            "n": 108,
            "percentage": 60.0
          },
          {
            "country": "Canada",
            "n": 27,
            "percentage": 15.0
          },
          {
            "country": "Germany",
            "n": 18,
            "percentage": 10.0
          },
          {
            "country": "France",
            "n": 13,
            "percentage": 7.2
          },
          {
            "country": "United Kingdom",
            "n": 9,
            "percentage": 5.0
          },
          {
            "country": "Australia",
            "n": 5,
            "percentage": 2.8
          }
        ]
      },
      "local_guidelines": {
        "guideline_name": "AAAAI/WAO HAE Guidelines 2023",
        "key_recommendations": [
          "Long-term prophylaxis for >= 2 attacks per month",
          "Target of zero attacks",
          "Approved agents: SC C1-INH, lanadelumab, berotralstat"
        ],
        "impact_on_feasibility": "Large registry (4,800 patients) with 180 clinical sites provides extensive characterized patient pool"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 6600,
        "registry_name": "US HAEA Patient Registry",
        "registry_size": 4800,
        "attack_freq_2plus": 2400,
        "attack_freq_3plus": 1800,
        "estimated_eligible_patients": 1100,
        "diagnostic_delay_years": 8.3
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 8.3,
          "diagnostic_tests_required": [
            "C4 level",
            "C1-INH level and function",
            "genetic testing for SERPING1"
          ],
          "specialist_type": "allergist/immunologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Long-term prophylaxis with C1-INH replacement or lanadelumab",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Subcutaneous C1-INH or lanadelumab prophylaxis"
            },
            {
              "line": 2,
              "therapy": "Berotralstat oral prophylaxis"
            }
          ]
        },
        "trial_phases": [
          {
            "phase": "screening",
            "duration": "2 weeks",
            "visits": 2
          },
          {
            "phase": "run_in",
            "duration": "4 weeks",
            "visits": 4,
            "procedures": [
              "attack diary recording"
            ]
          },
          {
            "phase": "treatment",
            "duration": "26 weeks",
            "visits": 13,
            "visit_frequency": "every 2 weeks"
          }
        ],
        "participation_barriers": [
          "run-in period with attack monitoring",
          "attack rate threshold for eligibility"
        ],
        "country": "United States",
        "region": "North America"
      }
    },
    {
      "doc_id": "06_gaucher_disease_brazil.pdf",
      "disease": "Gaucher Disease",
      "country": "Brazil",
      "study_design": null,
      "eligibility_inclusion": [],
      "eligibility_exclusion": [],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 57,000",
          "geography": "Brazil",
          "source": "ICGG Gaucher Registry"
        },
        {
          "data_type": "incidence",
          "value": "1 in 60,000 live births",
          "geography": "Brazil"
        }
      ],
      "screening_flow": {
        "screen_failure_rate_avg": "30-40%",
        "screening_to_randomization_ratio": "2.5:1"
      },
      "operational_burden": null,
      "endpoints": [],
      "sites_and_investigators": {
        "investigator_count": 28,
        "centres_with_trial_experience": 18,
        "pi_experienced": 10
      },
      "local_guidelines": {
        "guideline_name": "Brazilian Society of Medical Genetics and Genomics Gaucher Disease Guidelines 2024",
        "key_recommendations": [
          "Imiglucerase 60 U/kg IV every 2 weeks (first-line ERT)",
          "Eliglustat as second-line SRT",
          "Treatment via SUS high-cost medication program",
          "CBC monitoring every 3 months"
        ],
        "impact_on_feasibility": "SUS coverage enables treatment access; 32 reference centres but regional disparity (58% in Southeast); supply chain disruptions in 40% of pharmacies"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 3700,
        "registry_name": "ICGG Gaucher Registry",
        "registry_size": 2200,
        "stable_ert": 1600,
        "treatment_naive": 480,
        "estimated_eligible_trial": 340,
        "diagnostic_delay_years": 7.4,
        "referral_centres": 32
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 10.0,
          "diagnostic_tests_required": [
            "glucocerebrosidase enzyme assay",
            "GBA gene sequencing",
            "bone marrow biopsy"
          ],
          "specialist_type": "hematologist or metabolic specialist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "ERT with imiglucerase or velaglucerase alfa",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "ERT (imiglucerase IV every 2 weeks)"
            },
            {
              "line": 2,
              "therapy": "Substrate reduction therapy (eliglustat)"
            }
          ]
        },
        "participation_barriers": [
          "limited access to ERT in rural areas",
          "diagnostic delay due to low disease awareness",
          "travel to referral centres"
        ],
        "country": "Brazil",
        "region": "South America"
      }
    },
    {
      "doc_id": "07_cf_canada.pdf",
      "disease": "Cystic Fibrosis",
      "country": "Canada",
      "study_design": {
        "phase": "2",
        "design_type": "parallel",
        "blinding": "double-blind",
        "randomization_ratio": "3:1",
        "sample_size": null,
        "actual_enrollment": 96,
        "duration_months": 3,
        "treatment_arms": [
          {
            "name": "VX-121/tezacaftor/VX-561",
            "n": 72
          },
          {
            "name": "Placebo",
            "n": 24
          }
        ],
        "control_type": "placebo",
        "setting": "multi-centre",
        "sites_total": 18,
        "countries_total": 4
      },
      "eligibility_inclusion": [
        {
          "text": "Age 18 to 55 years",
          "category": "age"
        },
        {
          "text": "Confirmed CF with sweat chloride >= 60 mmol/L",
          "category": "disease_definition"
        },
        {
          "text": "Homozygous for F508del-CFTR mutation",
          "category": "biomarker"
        },
        {
          "text": "ppFEV1 >= 40% and <= 90% at screening",
          "category": "functional_status"
        },
        {
          "text": "Stable pulmonary status for at least 28 days",
          "category": "disease_stability"
        },
        {
          "text": "Willing to undergo washout of current CFTR modulator for 28 days",
          "category": "washout"
        }
      ],
      "eligibility_exclusion": [
        {
          "text": "Sputum culture positive for Burkholderia cepacia complex within 24 months",
          "category": "infection"
        },
        {
          "text": "History of solid organ transplantation",
          "category": "medical_history"
        },
        {
          "text": "ALT or AST > 3x ULN or total bilirubin > 2x ULN",
          "category": "organ_function"
        },
        {
          "text": "Pregnancy or breastfeeding",
          "category": "pregnancy"
        },
        {
          "text": "Use of strong CYP3A inducers or inhibitors within 14 days",
          "category": "concomitant_therapy"
        },
        {
          "text": "Pulmonary exacerbation requiring IV antibiotics within 28 days",
          "category": "disease_stability"
        }
      ],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 3,600 live births",
          "geography": "Canada"
        },
        {
          "data_type": "population",
          "value": "4,300 Canadians with CF",
          "geography": "Canada"
        }
      ],
      "screening_flow": {
        "screened": 136,
        "screen_failures": 40,
        "randomized": 96,
        "treated": 94,
        "completed": 88,
        "screen_failure_rate": 29.4,
        "screen_fail_reasons": [
          {
            "reason": "ppFEV1 outside required range",
            "count": 14,
            "percentage": 35.0
          },
          {
            "reason": "Positive Burkholderia cepacia complex culture",
            "count": 8,
            "percentage": 20.0
          },
          {
            "reason": "Unstable pulmonary status within 28 days",
            "count": 7,
            "percentage": 17.5
          },
          {
            "reason": "Abnormal liver function tests",
            "count": 6,
            "percentage": 15.0
          },
          {
            "reason": "Withdrawal of consent",
            "count": 5,
            "percentage": 12.5
          }
        ]
      },
      "operational_burden": {
        "visit_schedule": {
          "total_visits": 10,
          "frequency": "screening, baseline, Weeks 1,2,4,6,8,10,12,16"
        },
        "central_lab_required": true,
        "central_lab_analytes": [
          "liver function panel",
          "CBC",
          "renal function",
          "fasting glucose"
        ],
        "hard_gates": [
          "F508del homozygous genotype",
          "CFTR modulator washout"
        ]
      },
      "endpoints": [
        {
          "type": "primary",
          "name": "Absolute change in ppFEV1",
          "timepoint": "Week 12"
        },
        {
          "type": "secondary",
          "name": "Change in sweat chloride",
          "timepoint": "Week 12"
        },
        {
          "type": "secondary",
          "name": "CFQ-R respiratory domain score change"
        },
        {
          "type": "secondary",
          "name": "Rate of pulmonary exacerbations"
        },
        {
          "type": "safety",
          "name": "Liver function, ophthalmologic, ECG",
          "timepoint": "12 weeks"
        }
      ],
      "sites_and_investigators": {
        "total_sites": 18,
        "total_countries": 4,
        "countries": [
          "Canada",
          "United States",
          "Australia",
          "United Kingdom"
        ],
        "investigator_requirements": "accredited CF care centre with pulmonologist having >= 2 years CF trial experience, patient panel >= 30",
        "country_enrollment": [
          {
            "country": "Canada",
            "n": 42,
            "percentage": 43.8
          },
          {
            "country": "United States",
            "n": 30,
            "percentage": 31.3
          },
          {
            "country": "Australia",
            "n": 14,
            "percentage": 14.6
          },
          {
            "country": "United Kingdom",
            "n": 10,
            "percentage": 10.4
          }
        ]
      },
      "local_guidelines": {
        "guideline_name": "Cystic Fibrosis Canada Clinical Guidelines 2023",
        "key_recommendations": [
          "ETI for all patients >= 2 years with at least one F508del allele",
          "82% of eligible patients on CFTR modulator therapy",
          "Quarterly clinic visits with spirometry",
          "Annual comprehensive assessment"
        ],
        "impact_on_feasibility": "98% of CF patients captured in Canadian CF Registry; 42 accredited clinics nationwide"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 4300,
        "f508del_homozygous": 2020,
        "age_lung_eligible": 1200,
        "estimated_eligible_patients": 680,
        "registry_name": "Canadian Cystic Fibrosis Registry",
        "registry_size": 4300
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 0.5,
          "diagnostic_tests_required": [
            "sweat chloride test",
            "CFTR genotyping",
            "newborn screening"
          ],
          "specialist_type": "pulmonologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor)",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Elexacaftor/tezacaftor/ivacaftor (Trikafta)"
            },
            {
              "line": 2,
              "therapy": "Lumacaftor/ivacaftor for specific mutations"
            }
          ]
        },
        "trial_phases": [
          {
            "phase": "screening",
            "duration": "4 weeks",
            "visits": 3,
            "procedures": [
              "sweat chloride",
              "spirometry",
              "sputum culture"
            ]
          },
          {
            "phase": "treatment",
            "duration": "24 weeks",
            "visits": 6,
            "visit_frequency": "monthly"
          }
        ],
        "participation_barriers": [
          "CFTR genotype eligibility restriction",
          "infection control requirements",
          "stable baseline FEV1 requirement"
        ],
        "country": "Canada",
        "region": "North America"
      }
    },
    {
      "doc_id": "08_myasthenia_gravis_south_korea.pdf",
      "disease": "Myasthenia Gravis",
      "country": "South Korea",
      "study_design": {
        "phase": "3",
        "design_type": "parallel",
        "blinding": "double-blind",
        "randomization_ratio": "1:1",
        "sample_size": null,
        "actual_enrollment": 282,
        "duration_months": 3,
        "treatment_arms": [
          {
            "name": "Zilucoplan",
            "n": 141,
            "dose": "0.3 mg/kg",
            "frequency": "daily",
            "route": "subcutaneous"
          },
          {
            "name": "Placebo",
            "n": 141
          }
        ],
        "control_type": "placebo",
        "setting": "multi-centre",
        "sites_total": 52,
        "countries_total": 9
      },
      "eligibility_inclusion": [
        {
          "text": "Age 18 to 80 years",
          "category": "age"
        },
        {
          "text": "Confirmed gMG (MGFA class II, III, or IV)",
          "category": "disease_definition"
        },
        {
          "text": "Positive anti-AChR antibody (titer > 0.5 nmol/L)",
          "category": "biomarker"
        },
        {
          "text": "MG-ADL score >= 6, with at least 50% from non-ocular items",
          "category": "disease_severity"
        },
        {
          "text": "Stable MG treatment for at least 30 days",
          "category": "prior_therapy"
        },
        {
          "text": "Meningococcal vaccination at least 14 days before first dose",
          "category": "vaccination"
        }
      ],
      "eligibility_exclusion": [
        {
          "text": "MGFA class I (ocular only) or class V (intubated)",
          "category": "disease_severity"
        },
        {
          "text": "Thymectomy within 12 months",
          "category": "medical_history"
        },
        {
          "text": "Plasma exchange or IVIg within 4 weeks",
          "category": "washout"
        },
        {
          "text": "Active infection at screening",
          "category": "infection"
        },
        {
          "text": "History of meningococcal infection",
          "category": "medical_history"
        },
        {
          "text": "Prior complement inhibitor therapy",
          "category": "prior_therapy"
        },
        {
          "text": "Severe renal impairment (eGFR < 30)",
          "category": "organ_function"
        }
      ],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "22.8 per 100,000",
          "geography": "South Korea",
          "source": "National Health Insurance Service database"
        },
        {
          "data_type": "incidence",
          "value": "2.1 per 100,000 person-years",
          "geography": "South Korea"
        }
      ],
      "screening_flow": {
        "screened": 410,
        "screen_failures": 128,
        "randomized": 282,
        "treated": 278,
        "completed": 256,
        "discontinued": 26,
        "screen_failure_rate": 31.2,
        "screen_fail_reasons": [
          {
            "reason": "MG-ADL score below threshold",
            "count": 48,
            "percentage": 37.5
          },
          {
            "reason": "Anti-AChR antibody negative",
            "count": 28,
            "percentage": 21.9
          },
          {
            "reason": "Inadequate meningococcal vaccination status",
            "count": 22,
            "percentage": 17.2
          },
          {
            "reason": "Unstable immunosuppressive therapy",
            "count": 16,
            "percentage": 12.5
          },
          {
            "reason": "Other reasons",
            "count": 14,
            "percentage": 10.9
          }
        ],
        "reasons_can_overlap": true
      },
      "operational_burden": {
        "vaccination_requirements": [
          {
            "vaccine_type": "meningococcal tetravalent conjugate and serogroup B",
            "requirement_type": "required",
            "timing": "at least 14 days before first dose"
          }
        ],
        "visit_schedule": {
          "total_visits": 10,
          "frequency": "screening, baseline, Weeks 1,2,4,6,8,10,12,20"
        },
        "central_lab_required": true,
        "central_lab_analytes": [
          "anti-AChR antibody titers",
          "complement levels (CH50, C3, C4, sC5b-9)",
          "liver function panel",
          "CBC"
        ],
        "hard_gates": [
          "meningococcal vaccination",
          "anti-AChR antibody positivity"
        ]
      },
      "endpoints": [
        {
          "type": "primary",
          "name": "Change in MG-ADL score",
          "timepoint": "Week 12"
        },
        {
          "type": "secondary",
          "name": "Change in QMG score",
          "timepoint": "Week 12"
        },
        {
          "type": "secondary",
          "name": "Change in MG-Composite score"
        },
        {
          "type": "secondary",
          "name": "Proportion achieving minimal symptom expression (MG-ADL <= 1)"
        },
        {
          "type": "secondary",
          "name": "MG-QoL15r change"
        },
        {
          "type": "safety",
          "name": "Meningococcal monitoring, injection site reactions, liver function"
        }
      ],
      "sites_and_investigators": {
        "total_sites": 52,
        "total_countries": 9,
        "countries": [
          "South Korea",
          "Japan",
          "United States",
          "Canada",
          "Germany",
          "France",
          "United Kingdom",
          "Italy",
          "Australia"
        ],
        "investigator_requirements": "board-certified neurologist with neuromuscular experience, QMG scoring proficiency",
        "country_enrollment": [
          {
            "country": "South Korea",
            "n": 72,
            "percentage": 25.5
          },
          {
            "country": "United States",
            "n": 58,
            "percentage": 20.6
          },
          {
            "country": "Japan",
            "n": 42,
            "percentage": 14.9
          },
          {
            "country": "Germany",
            "n": 32,
            "percentage": 11.3
          },
          {
            "country": "France",
            "n": 24,
            "percentage": 8.5
          },
          {
            "country": "United Kingdom",
            "n": 20,
            "percentage": 7.1
          },
          {
            "country": "Canada",
            "n": 16,
            "percentage": 5.7
          },
          {
            "country": "Italy",
            "n": 12,
            "percentage": 4.3
          },
          {
            "country": "Australia",
            "n": 6,
            "percentage": 2.1
          }
        ]
      },
      "local_guidelines": {
        "guideline_name": "Korean Neurological Association MG Treatment Guidelines 2023",
        "key_recommendations": [
          "Pyridostigmine first-line",
          "Corticosteroids and steroid-sparing agents for inadequate response",
          "Rituximab for refractory gMG",
          "Meningococcal vaccination mandatory before complement inhibitors"
        ],
        "impact_on_feasibility": "Korean MG Registry (6,500 patients) enables efficient pre-screening; 38 neuromuscular centres; diagnostic delay 2.1 years (below global average)"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 11800,
        "anti_achr_positive": 9400,
        "mg_adl_6plus": 4200,
        "estimated_eligible_patients": 2800,
        "registry_name": "Korean MG Registry",
        "registry_size": 6500,
        "diagnostic_delay_years": 2.1,
        "referral_centres": 38
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 2.0,
          "diagnostic_tests_required": [
            "anti-AChR antibody test",
            "electromyography",
            "CT of thymus"
          ],
          "specialist_type": "neurologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Acetylcholinesterase inhibitors + corticosteroids + immunosuppression",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Pyridostigmine + prednisone"
            },
            {
              "line": 2,
              "therapy": "Azathioprine or mycophenolate mofetil"
            }
          ]
        },
        "trial_phases": [
          {
            "phase": "screening",
            "duration": "4 weeks",
            "visits": 3
          },
          {
            "phase": "treatment",
            "duration": "26 weeks",
            "visits": 7,
            "visit_frequency": "every 4 weeks"
          }
        ],
        "participation_barriers": [
          "QMG score threshold for eligibility",
          "stable immunosuppression requirement",
          "thymectomy status"
        ],
        "country": "South Korea",
        "region": "Asia-Pacific"
      }
    },
    {
      "doc_id": "09_pbc_italy.pdf",
      "disease": "Primary Biliary Cholangitis",
      "country": "Italy",
      "study_design": null,
      "eligibility_inclusion": [],
      "eligibility_exclusion": [],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "27.6 per 100,000",
          "geography": "Italy"
        },
        {
          "data_type": "incidence",
          "value": "3.4 per 100,000 person-years",
          "geography": "Italy"
        },
        {
          "data_type": "prevalence",
          "value": "34.2 per 100,000",
          "geography": "Veneto, Italy"
        },
        {
          "data_type": "prevalence",
          "value": "18.5 per 100,000",
          "geography": "Sicily, Italy"
        }
      ],
      "screening_flow": {
        "screen_failure_rate_avg": "25-30%"
      },
      "operational_burden": null,
      "endpoints": [],
      "sites_and_investigators": {
        "investigator_count": 52,
        "centres_with_experience": 35,
        "pi_experienced": 22
      },
      "local_guidelines": {
        "guideline_name": "AISF/SIGE PBC Clinical Practice Guidelines 2024",
        "key_recommendations": [
          "UDCA 13-15 mg/kg/day first-line for all patients",
          "Obeticholic acid add-on for non-responders",
          "Paris II or Barcelona response criteria at 12 months",
          "Transient elastography annually",
          "Seladelpar and elafibranor for OCA-intolerant patients"
        ],
        "impact_on_feasibility": "48 hepatology centres in registry, Italy top-3 enrolling country in global PBC phase 3 trials; large UDCA non-responder pool"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 16300,
        "registry_name": "Italian PBC Registry (AISF)",
        "registry_size": 9200,
        "on_udca": 6800,
        "udca_non_responders": 2400,
        "estimated_eligible_patients": 1600,
        "diagnostic_delay_years": 3.8,
        "referral_centres": 48
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 4.0,
          "diagnostic_tests_required": [
            "anti-mitochondrial antibody (AMA)",
            "liver function tests",
            "liver biopsy"
          ],
          "specialist_type": "hepatologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Ursodeoxycholic acid (UDCA) as first-line",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "UDCA 13-15 mg/kg/day"
            },
            {
              "line": 2,
              "therapy": "Obeticholic acid for UDCA non-responders"
            }
          ]
        },
        "participation_barriers": [
          "UDCA response assessment period",
          "liver biopsy for staging",
          "predominantly female patient population"
        ],
        "country": "Italy",
        "region": "Europe"
      }
    },
    {
      "doc_id": "10_dmd_australia.pdf",
      "disease": "Duchenne Muscular Dystrophy",
      "country": "Australia",
      "study_design": {
        "phase": "2",
        "design_type": "parallel",
        "blinding": "double-blind",
        "randomization_ratio": "2:1",
        "sample_size": null,
        "actual_enrollment": 54,
        "duration_months": 12,
        "treatment_arms": [
          {
            "name": "Casimersen",
            "n": 36,
            "dose": "30 mg/kg",
            "frequency": "weekly",
            "route": "IV"
          },
          {
            "name": "Placebo",
            "n": 18
          }
        ],
        "control_type": "placebo",
        "setting": "multi-centre",
        "sites_total": 22,
        "countries_total": 6
      },
      "eligibility_inclusion": [
        {
          "text": "Males aged 6 to 12 years",
          "category": "age"
        },
        {
          "text": "Genetically confirmed DMD amenable to exon 45 skipping",
          "category": "biomarker"
        },
        {
          "text": "Ambulatory: >= 300 meters on 6MWT",
          "category": "functional_status"
        },
        {
          "text": "Stable corticosteroid regimen for at least 6 months, no dose change > 20%",
          "category": "prior_therapy"
        },
        {
          "text": "NSAA score >= 15",
          "category": "functional_status"
        }
      ],
      "eligibility_exclusion": [
        {
          "text": "Non-ambulatory or wheelchair for community mobility",
          "category": "functional_status"
        },
        {
          "text": "Previous exon-skipping or gene therapy",
          "category": "prior_therapy"
        },
        {
          "text": "FVC < 50% predicted",
          "category": "organ_function"
        },
        {
          "text": "LVEF < 50%",
          "category": "cardiac"
        },
        {
          "text": "Severe scoliosis (Cobb angle > 20 degrees)",
          "category": "medical_history"
        },
        {
          "text": "Surgery planned within study period",
          "category": "other"
        },
        {
          "text": "Current use of other investigational treatment",
          "category": "other_trial"
        }
      ],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 5,000 male live births",
          "geography": "Australia"
        },
        {
          "data_type": "population",
          "value": "approximately 600 males in Australia",
          "geography": "Australia"
        }
      ],
      "screening_flow": {
        "screened": 84,
        "screen_failures": 30,
        "randomized": 54,
        "treated": 52,
        "completed": 48,
        "screen_failure_rate": 35.7,
        "screen_fail_reasons": [
          {
            "reason": "Non-ambulatory at screening",
            "count": 10,
            "percentage": 33.3
          },
          {
            "reason": "Mutation not amenable to exon 45 skipping on central genetic confirmation",
            "count": 8,
            "percentage": 26.7
          },
          {
            "reason": "Corticosteroid dose not stable for 6 months",
            "count": 6,
            "percentage": 20.0
          },
          {
            "reason": "Unable to complete 6MWT >= 300 meters",
            "count": 4,
            "percentage": 13.3
          },
          {
            "reason": "LVEF < 50%",
            "count": 2,
            "percentage": 6.7
          }
        ]
      },
      "operational_burden": {
        "invasive_procedures": [
          {
            "name": "muscle biopsy (biceps brachii)",
            "timing": [
              "baseline",
              "Week 48"
            ],
            "purpose": "efficacy_assessment",
            "is_eligibility_requirement": false
          }
        ],
        "visit_schedule": {
          "total_visits": 59,
          "frequency": "weekly IV infusions (52) plus 7 assessment visits"
        },
        "central_lab_required": true,
        "central_lab_analytes": [
          "CBC",
          "renal function",
          "liver function",
          "creatine kinase",
          "complement C3/C4"
        ],
        "hard_gates": [
          "exon 45 skipping amenable mutation",
          "ambulatory status",
          "muscle biopsy"
        ]
      },
      "endpoints": [
        {
          "type": "primary",
          "name": "Change in dystrophin protein by Western blot on muscle biopsy",
          "timepoint": "Week 48"
        },
        {
          "type": "secondary",
          "name": "Change in 6MWT distance",
          "timepoint": "Week 48"
        },
        {
          "type": "secondary",
          "name": "Change in NSAA total score"
        },
        {
          "type": "secondary",
          "name": "Change in rise-from-floor time"
        },
        {
          "type": "safety",
          "name": "Renal function, platelet counts, complement markers",
          "timepoint": "48 weeks"
        }
      ],
      "sites_and_investigators": {
        "total_sites": 22,
        "total_countries": 6,
        "countries": [
          "Australia",
          "United States",
          "United Kingdom",
          "Canada",
          "Germany",
          "Italy"
        ],
        "investigator_requirements": "pediatric neurologist with >= 2 years DMD trial experience, certified 6MWT/NSAA physiotherapy team, pediatric anesthesia for biopsy",
        "country_enrollment": [
          {
            "country": "Australia",
            "n": 14,
            "percentage": 25.9
          },
          {
            "country": "United States",
            "n": 16,
            "percentage": 29.6
          },
          {
            "country": "United Kingdom",
            "n": 10,
            "percentage": 18.5
          },
          {
            "country": "Canada",
            "n": 6,
            "percentage": 11.1
          },
          {
            "country": "Germany",
            "n": 5,
            "percentage": 9.3
          },
          {
            "country": "Italy",
            "n": 3,
            "percentage": 5.6
          }
        ]
      },
      "local_guidelines": {
        "guideline_name": "Muscular Dystrophy Australia Clinical Guidelines 2023",
        "key_recommendations": [
          "Corticosteroid therapy from symptom onset",
          "Annual echocardiography from diagnosis",
          "Pulmonary function testing from age 6",
          "Bone health DXA annually on steroids",
          "Access to exon-skipping via TGA Special Access Scheme"
        ]
      },
      "patient_population": {
        "estimated_diagnosed_patients": 600,
        "exon_45_amenable": 125,
        "ambulatory_age_eligible": 50,
        "registry_name": "TREAT-NMD / Australian National Neuromuscular Disease Registry",
        "referral_centres": 8
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 4.5,
          "diagnostic_tests_required": [
            "creatine kinase level",
            "dystrophin gene testing",
            "muscle biopsy"
          ],
          "specialist_type": "pediatric neurologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Corticosteroids (deflazacort or prednisone)",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Deflazacort 0.9 mg/kg/day"
            },
            {
              "line": 2,
              "therapy": "Exon-skipping therapies for amenable mutations"
            }
          ]
        },
        "trial_phases": [
          {
            "phase": "screening",
            "duration": "4 weeks",
            "visits": 3,
            "procedures": [
              "genetic confirmation",
              "6MWT",
              "timed function tests"
            ]
          },
          {
            "phase": "treatment",
            "duration": "48 weeks",
            "visits": 12,
            "visit_frequency": "monthly"
          }
        ],
        "participation_barriers": [
          "ambulatory status requirement",
          "age restriction (pediatric)",
          "specific exon mutation eligibility"
        ],
        "country": "Australia",
        "region": "Asia-Pacific"
      }
    },
    {
      "doc_id": "11_sickle_cell_nigeria.pdf",
      "disease": "Sickle Cell Disease",
      "country": "Nigeria",
      "study_design": null,
      "eligibility_inclusion": [],
      "eligibility_exclusion": [],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "2-3% of population (HbSS genotype)",
          "geography": "Nigeria"
        },
        {
          "data_type": "population",
          "value": "4-6 million affected individuals",
          "geography": "Nigeria"
        },
        {
          "data_type": "incidence",
          "value": "150,000 newborns with SCD annually",
          "geography": "Nigeria"
        }
      ],
      "screening_flow": {
        "screen_failure_rate_avg": "45-55%",
        "screening_to_randomization_ratio": "3.5:1 to 5:1"
      },
      "operational_burden": null,
      "endpoints": [],
      "sites_and_investigators": {
        "investigator_count": 32,
        "centres_with_trial_experience": 18,
        "pi_experienced": 12
      },
      "local_guidelines": {
        "guideline_name": "Federal Ministry of Health Nigeria SCD Guidelines 2024",
        "key_recommendations": [
          "Hydroxyurea for all SCD >= 9 months (HbSS/HbS-beta-zero)",
          "Start 15 mg/kg/day, titrate to 25-35 mg/kg/day",
          "Chronic exchange transfusion for stroke prevention",
          "TCD ultrasonography annually ages 2-16"
        ],
        "impact_on_feasibility": "Massive patient pool but < 500,000 under active follow-up; infrastructure challenges: unreliable electricity (65% of centres), limited internet (60%), extended regulatory timeline (6-8 months NAFDAC)"
      },
      "patient_population": {
        "estimated_affected": 5000000,
        "under_active_followup": 500000,
        "age_eligible_hbss": 280000,
        "on_stable_hydroxyurea": 120000,
        "estimated_eligible_broad": 60000,
        "registry_name": "National SCD Registry",
        "registry_size": 85000,
        "diagnostic_delay_years": 4.6,
        "referral_centres": 52
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 2.0,
          "diagnostic_tests_required": [
            "hemoglobin electrophoresis",
            "HbSS confirmation",
            "complete blood count"
          ],
          "specialist_type": "hematologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Hydroxyurea + folic acid supplementation",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Hydroxyurea"
            },
            {
              "line": 2,
              "therapy": "L-glutamine or crizanlizumab"
            }
          ]
        },
        "participation_barriers": [
          "limited rural healthcare access",
          "hydroxyurea availability",
          "high baseline transfusion dependence"
        ],
        "country": "Nigeria",
        "region": "Unknown"
      }
    },
    {
      "doc_id": "12_systemic_mastocytosis_spain.pdf",
      "disease": "Advanced Systemic Mastocytosis",
      "country": "Spain",
      "study_design": {
        "phase": "2",
        "design_type": "parallel",
        "blinding": "open-label",
        "randomization_ratio": "2:1",
        "sample_size": null,
        "actual_enrollment": 66,
        "duration_months": 6,
        "treatment_arms": [
          {
            "name": "Avapritinib",
            "n": 44,
            "dose": "200 mg",
            "frequency": "daily",
            "route": "oral"
          },
          {
            "name": "Best available therapy",
            "n": 22
          }
        ],
        "control_type": "active_comparator",
        "setting": "multi-centre",
        "sites_total": 28,
        "countries_total": 7
      },
      "eligibility_inclusion": [
        {
          "text": "Age >= 18 years",
          "category": "age"
        },
        {
          "text": "Centrally confirmed AdvSM (ASM, SM-AHN, or MCL) per WHO 2022",
          "category": "disease_definition"
        },
        {
          "text": "KIT D816V mutation confirmed by central digital PCR (allele burden >= 0.1%)",
          "category": "biomarker"
        },
        {
          "text": "At least 1 evaluable C-finding",
          "category": "disease_severity"
        },
        {
          "text": "ECOG PS 0, 1, or 2",
          "category": "functional_status"
        },
        {
          "text": "Platelet count >= 50,000/mm3",
          "category": "lab_value"
        },
        {
          "text": "Adequate hepatic function: bilirubin <= 1.5x ULN, ALT/AST <= 3x ULN",
          "category": "organ_function"
        }
      ],
      "eligibility_exclusion": [
        {
          "text": "Indolent SM or smoldering SM without C-findings",
          "category": "disease_definition"
        },
        {
          "text": "Prior selective KIT D816V inhibitor",
          "category": "prior_therapy"
        },
        {
          "text": "Known additional actionable mutation",
          "category": "biomarker"
        },
        {
          "text": "Active bleeding or intracranial hemorrhage within 6 months",
          "category": "medical_history"
        },
        {
          "text": "Concurrent malignancy requiring systemic treatment",
          "category": "other"
        },
        {
          "text": "QTc > 480 ms",
          "category": "cardiac"
        }
      ],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "0.5 per 100,000",
          "geography": "Spain"
        },
        {
          "data_type": "population",
          "value": "approximately 240 diagnosed patients",
          "geography": "Spain"
        },
        {
          "data_type": "incidence",
          "value": "0.04 per 100,000 per year",
          "geography": "Spain"
        }
      ],
      "screening_flow": {
        "screened": 102,
        "screen_failures": 36,
        "randomized": 66,
        "treated": 64,
        "completed": 54,
        "discontinued": 12,
        "screen_failure_rate": 35.3,
        "screen_fail_reasons": [
          {
            "reason": "KIT D816V not confirmed by central digital PCR",
            "count": 12,
            "percentage": 33.3
          },
          {
            "reason": "SM subtype reclassified to indolent SM",
            "count": 8,
            "percentage": 22.2
          },
          {
            "reason": "Platelet count < 50,000/mm3",
            "count": 6,
            "percentage": 16.7
          },
          {
            "reason": "ECOG PS > 2",
            "count": 5,
            "percentage": 13.9
          },
          {
            "reason": "Other (QTc, concurrent malignancy)",
            "count": 5,
            "percentage": 13.9
          }
        ]
      },
      "operational_burden": {
        "invasive_procedures": [
          {
            "name": "bone marrow biopsy",
            "timing": [
              "screening",
              "Week 12",
              "Week 24"
            ],
            "purpose": "response_assessment",
            "is_eligibility_requirement": true
          }
        ],
        "visit_schedule": {
          "total_visits": 14,
          "frequency": "screening, baseline, Wk1,2,4,8,12,16,20,24,28,32,36,48"
        },
        "central_lab_required": true,
        "central_lab_analytes": [
          "serum tryptase",
          "CBC with differential",
          "liver and renal function",
          "coagulation",
          "alkaline phosphatase"
        ],
        "hard_gates": [
          "central KIT D816V confirmation",
          "central pathology review",
          "bone marrow biopsy"
        ]
      },
      "endpoints": [
        {
          "type": "primary",
          "name": "Overall response rate by IWG-MRT-ECNM criteria",
          "timepoint": "Week 24"
        },
        {
          "type": "secondary",
          "name": "Duration of response"
        },
        {
          "type": "secondary",
          "name": "Change in serum tryptase"
        },
        {
          "type": "secondary",
          "name": "Change in KIT D816V allele burden"
        },
        {
          "type": "secondary",
          "name": "AdvSM-SAF symptom response"
        },
        {
          "type": "safety",
          "name": "Intracranial hemorrhage, cognitive effects, edema, cytopenias"
        }
      ],
      "sites_and_investigators": {
        "total_sites": 28,
        "total_countries": 7,
        "countries": [
          "Spain",
          "Germany",
          "United States",
          "France",
          "Italy",
          "United Kingdom",
          "Sweden"
        ],
        "country_enrollment": [
          {
            "country": "Spain",
            "n": 22,
            "percentage": 33.3
          },
          {
            "country": "Germany",
            "n": 12,
            "percentage": 18.2
          },
          {
            "country": "United States",
            "n": 10,
            "percentage": 15.2
          },
          {
            "country": "France",
            "n": 8,
            "percentage": 12.1
          },
          {
            "country": "Italy",
            "n": 6,
            "percentage": 9.1
          },
          {
            "country": "United Kingdom",
            "n": 5,
            "percentage": 7.6
          },
          {
            "country": "Sweden",
            "n": 3,
            "percentage": 4.5
          }
        ]
      },
      "local_guidelines": {
        "guideline_name": "SEHH (Spanish Society of Hematology) AdvSM Guidelines",
        "key_recommendations": [
          "Cytoreductive therapy for C-findings",
          "Midostaurin or avapritinib first-line",
          "Bone marrow biopsy at diagnosis and every 6 months",
          "KIT D816V digital PCR for diagnosis and monitoring"
        ],
        "impact_on_feasibility": "REMA network (world's largest, 5,200 patients, 14 centres) provides decisive advantage; centralized reference laboratory in Toledo"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 240,
        "registry_name": "REMA (Red Española de Mastocitosis)",
        "registry_size": 5200,
        "advsm_in_registry": 420,
        "active_c_findings": 120,
        "estimated_eligible": 80,
        "referral_centres": 14
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 6.0,
          "diagnostic_tests_required": [
            "bone marrow biopsy",
            "KIT D816V mutation analysis",
            "serum tryptase"
          ],
          "specialist_type": "hematologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Midostaurin for advanced SM",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Midostaurin"
            },
            {
              "line": 2,
              "therapy": "Avapritinib for advanced SM"
            }
          ]
        },
        "trial_phases": [
          {
            "phase": "screening",
            "duration": "4 weeks",
            "visits": 3,
            "procedures": [
              "bone marrow biopsy",
              "CT imaging",
              "blood draw"
            ]
          },
          {
            "phase": "treatment",
            "duration": "24 weeks",
            "visits": 6,
            "visit_frequency": "monthly"
          }
        ],
        "participation_barriers": [
          "bone marrow biopsy gate",
          "KIT mutation confirmation requirement",
          "rare disease with very limited patient pool"
        ],
        "country": "Spain",
        "region": "Europe"
      }
    },
    {
      "doc_id": "13_niemann_pick_c_netherlands.pdf",
      "disease": "Niemann-Pick Disease Type C",
      "country": "Netherlands",
      "study_design": null,
      "eligibility_inclusion": [],
      "eligibility_exclusion": [],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 120,000",
          "geography": "Netherlands"
        },
        {
          "data_type": "incidence",
          "value": "1 in 150,000 live births",
          "geography": "Netherlands"
        },
        {
          "data_type": "prevalence",
          "value": "1 in 100,000",
          "geography": "Europe"
        }
      ],
      "screening_flow": {
        "screen_failure_rate_avg": "30-40%",
        "screening_to_randomization_ratio": "2.5:1 to 3.0:1"
      },
      "operational_burden": null,
      "endpoints": [],
      "sites_and_investigators": {
        "total_sites": 6,
        "total_countries": 1,
        "countries": [
          "Netherlands"
        ],
        "investigator_count": 8,
        "pi_experienced": 5,
        "european_network_sites": 45,
        "european_investigators": 68
      },
      "local_guidelines": {
        "guideline_name": "Dutch Society for Inborn Errors of Metabolism / MetabERN NPC Guidelines 2024",
        "key_recommendations": [
          "Miglustat 200 mg TID for neurological NPC",
          "Plasma oxysterols first-line screening",
          "NPC1/NPC2 genetic testing for confirmation",
          "NPC-CSS scoring every 6 months",
          "Early treatment initiation recommended"
        ],
        "impact_on_feasibility": "6 metabolic centres ensuring < 150 km travel for any patient; Amsterdam UMC as national coordinating centre; international pooling essential due to ultra-rare nature"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 145,
        "registry_name": "Dutch NPC Registry (Amsterdam UMC) / European NPC Registry (INPDA)",
        "registry_size_dutch": 88,
        "registry_size_european": 680,
        "on_miglustat": 72,
        "ambulatory_age_eligible": 45,
        "estimated_eligible_trial": 30,
        "diagnostic_delay_years": 5.6,
        "referral_centres": 6,
        "typical_contribution_per_trial": "8-12 patients"
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 8.0,
          "diagnostic_tests_required": [
            "filipin staining",
            "NPC1/NPC2 gene sequencing",
            "plasma oxysterol levels"
          ],
          "specialist_type": "metabolic disease specialist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Miglustat (substrate reduction therapy)",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Miglustat 200 mg three times daily"
            },
            {
              "line": 2,
              "therapy": "Arimoclomol (investigational)"
            }
          ]
        },
        "participation_barriers": [
          "ultra-rare disease with extremely limited patient pool",
          "complex diagnostic workup",
          "expert centres concentrated in Amsterdam"
        ],
        "country": "Netherlands",
        "region": "Europe"
      }
    },
    {
      "doc_id": "14_iga_nephropathy_china.pdf",
      "disease": "IgA Nephropathy",
      "country": "China",
      "study_design": {
        "phase": "3",
        "design_type": "parallel",
        "blinding": "double-blind",
        "randomization_ratio": "1:1",
        "sample_size": null,
        "actual_enrollment": 360,
        "duration_months": 9,
        "treatment_arms": [
          {
            "name": "Sparsentan",
            "n": 180,
            "dose": "400 mg",
            "frequency": "daily",
            "route": "oral"
          },
          {
            "name": "Irbesartan",
            "n": 180,
            "dose": "300 mg",
            "frequency": "daily",
            "route": "oral"
          }
        ],
        "control_type": "active_comparator",
        "setting": "multi-centre",
        "sites_total": 65,
        "countries_total": 8
      },
      "eligibility_inclusion": [
        {
          "text": "Age 18 to 65 years",
          "category": "age"
        },
        {
          "text": "Biopsy-proven IgAN within 24 months",
          "category": "disease_definition"
        },
        {
          "text": "UPCR >= 1.0 g/g on two separate measurements despite maximally tolerated RAS inhibitor",
          "category": "lab_value"
        },
        {
          "text": "eGFR >= 30 mL/min/1.73m2",
          "category": "lab_value"
        },
        {
          "text": "Less than 50% glomeruli showing global sclerosis",
          "category": "disease_definition"
        }
      ],
      "eligibility_exclusion": [
        {
          "text": "Secondary IgAN (IgA vasculitis, lupus nephritis, liver cirrhosis)",
          "category": "disease_definition"
        },
        {
          "text": "Rapidly progressive GN (> 50% crescentic glomeruli)",
          "category": "disease_severity"
        },
        {
          "text": "Current or planned pregnancy",
          "category": "pregnancy"
        },
        {
          "text": "Systemic corticosteroids or immunosuppressants within 3 months",
          "category": "washout"
        },
        {
          "text": "History of kidney transplant",
          "category": "medical_history"
        },
        {
          "text": "Uncontrolled hypertension (SBP > 150 or DBP > 95)",
          "category": "vital_signs"
        }
      ],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "3.5 per 1,000 adults",
          "geography": "China"
        },
        {
          "data_type": "population",
          "value": "approximately 5 million",
          "geography": "China"
        }
      ],
      "screening_flow": {
        "screened": 520,
        "screen_failures": 160,
        "randomized": 360,
        "treated": 354,
        "completed": 328,
        "discontinued": 32,
        "screen_failure_rate": 30.8,
        "screen_fail_reasons": [
          {
            "reason": "UPCR below 1.0 g/g on repeat testing",
            "count": 62,
            "percentage": 38.8
          },
          {
            "reason": "eGFR below 30",
            "count": 28,
            "percentage": 17.5
          },
          {
            "reason": "Biopsy not within 24 months or >= 50% glomerulosclerosis",
            "count": 24,
            "percentage": 15.0
          },
          {
            "reason": "Uncontrolled hypertension",
            "count": 18,
            "percentage": 11.3
          },
          {
            "reason": "Withdrawal of consent",
            "count": 16,
            "percentage": 10.0
          },
          {
            "reason": "Other reasons",
            "count": 12,
            "percentage": 7.5
          }
        ]
      },
      "operational_burden": {
        "invasive_procedures": [
          {
            "name": "renal biopsy",
            "timing": [
              "within 24 months of screening"
            ],
            "purpose": "diagnosis_confirmation",
            "is_eligibility_requirement": true
          }
        ],
        "visit_schedule": {
          "total_visits": 11,
          "frequency": "screening (2 visits), baseline, Wk2,4,8,12,18,24,36,40"
        },
        "central_lab_required": true,
        "central_lab_analytes": [
          "UPCR",
          "serum creatinine",
          "eGFR",
          "serum albumin",
          "CBC",
          "liver function",
          "serum IgA"
        ],
        "hard_gates": [
          "biopsy-proven IgAN within 24 months",
          "UPCR threshold on repeat testing",
          "stable RAS inhibitor"
        ]
      },
      "endpoints": [
        {
          "type": "primary",
          "name": "Change in UPCR (log-transformed)",
          "timepoint": "Week 36"
        },
        {
          "type": "secondary",
          "name": "Proportion achieving UPCR < 0.5 g/g",
          "timepoint": "Week 36"
        },
        {
          "type": "secondary",
          "name": "Rate of eGFR decline (slope)"
        },
        {
          "type": "secondary",
          "name": "Change in serum albumin"
        },
        {
          "type": "safety",
          "name": "Hepatic function, edema, fluid retention",
          "timepoint": "36 weeks"
        }
      ],
      "sites_and_investigators": {
        "total_sites": 65,
        "total_countries": 8,
        "countries": [
          "China",
          "Japan",
          "South Korea",
          "United States",
          "Germany",
          "France",
          "United Kingdom",
          "Australia"
        ],
        "investigator_requirements": "nephrologist with >= 3 years glomerulonephritis experience, renal biopsy capability, patient panel >= 50 IgAN",
        "country_enrollment": [
          {
            "country": "China",
            "n": 186,
            "percentage": 51.7
          },
          {
            "country": "Japan",
            "n": 48,
            "percentage": 13.3
          },
          {
            "country": "South Korea",
            "n": 36,
            "percentage": 10.0
          },
          {
            "country": "United States",
            "n": 32,
            "percentage": 8.9
          },
          {
            "country": "Germany",
            "n": 24,
            "percentage": 6.7
          },
          {
            "country": "France",
            "n": 16,
            "percentage": 4.4
          },
          {
            "country": "United Kingdom",
            "n": 12,
            "percentage": 3.3
          },
          {
            "country": "Australia",
            "n": 6,
            "percentage": 1.7
          }
        ]
      },
      "local_guidelines": {
        "guideline_name": "Chinese Society of Nephrology IgAN Guidelines 2023",
        "key_recommendations": [
          "Maximal RAS inhibition first-line",
          "Target UPCR < 0.5 g/g",
          "Corticosteroids for persistent proteinuria > 1.0 g/day",
          "MMF for proliferative lesions",
          "Renal biopsy mandatory for diagnosis"
        ],
        "impact_on_feasibility": "World's largest IgAN registry (180,000 patients, 320 centres); China contributed >50% enrollment; IgAN accounts for 40-45% of all renal biopsies in China"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 5000000,
        "registry_name": "Chinese IgA Nephropathy Registry",
        "registry_size": 180000,
        "upcr_above_1": 45000,
        "estimated_eligible": 18000
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 1.5,
          "diagnostic_tests_required": [
            "renal biopsy",
            "urinalysis",
            "serum IgA levels"
          ],
          "specialist_type": "nephrologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "ACE inhibitor/ARB + corticosteroids for proteinuria > 1 g/day",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "ACEi/ARB optimization"
            },
            {
              "line": 2,
              "therapy": "Corticosteroid pulse therapy"
            }
          ]
        },
        "trial_phases": [
          {
            "phase": "screening",
            "duration": "8 weeks",
            "visits": 4,
            "procedures": [
              "renal biopsy confirmation",
              "24-hour urine collection",
              "blood draw"
            ]
          },
          {
            "phase": "run_in",
            "duration": "4 weeks",
            "visits": 2
          },
          {
            "phase": "treatment",
            "duration": "36 weeks",
            "visits": 9,
            "visit_frequency": "monthly"
          }
        ],
        "participation_barriers": [
          "renal biopsy requirement",
          "UPCR threshold for eligibility",
          "stable ACEi/ARB dose requirement"
        ],
        "country": "China",
        "region": "Unknown"
      }
    },
    {
      "doc_id": "15_eb_argentina.pdf",
      "disease": "Epidermolysis Bullosa",
      "country": "Argentina",
      "study_design": null,
      "eligibility_inclusion": [],
      "eligibility_exclusion": [],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 17,000",
          "geography": "Argentina"
        },
        {
          "data_type": "population",
          "value": "approximately 2,700 diagnosed",
          "geography": "Argentina"
        },
        {
          "data_type": "incidence",
          "value": "20 per million live births",
          "geography": "Argentina"
        }
      ],
      "screening_flow": {
        "screen_failure_rate_avg": "35-45%"
      },
      "operational_burden": null,
      "endpoints": [],
      "sites_and_investigators": {
        "investigator_count": 14,
        "centres_with_experience": 8,
        "pi_experienced": 4
      },
      "local_guidelines": {
        "guideline_name": "Argentine Society of Dermatology EB Guidelines 2024",
        "key_recommendations": [
          "Non-adherent dressings (Mepitel) first-line wound care",
          "Immunofluorescence mapping for subtype classification",
          "Genetic confirmation via CENAGEM",
          "Nutritional support 150% caloric intake for RDEB",
          "SCC surveillance starting age 15 for RDEB"
        ],
        "impact_on_feasibility": "12 RAEB centres but 42% patients in Buenos Aires; 6.2 year diagnostic delay; IFM only at 3 centres; DEBRA transport subsidies for 4 trips/year"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 2700,
        "registry_name": "RAEB (Registro Argentino de Epidermólisis Bullosa)",
        "registry_size": 1400,
        "dystrophic_eb": 530,
        "rdeb_confirmed_col7a1": 200,
        "estimated_eligible_rdeb_trial": 60,
        "diagnostic_delay_years": 6.2,
        "referral_centres": 12
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 1.0,
          "diagnostic_tests_required": [
            "skin biopsy with immunofluorescence mapping",
            "genetic testing for COL7A1/LAMB3/etc"
          ],
          "specialist_type": "dermatologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Wound care management + pain control",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Advanced wound care dressings"
            },
            {
              "line": 2,
              "therapy": "Gene therapy (investigational) or bone marrow transplant"
            }
          ]
        },
        "participation_barriers": [
          "specialized wound care assessment",
          "genetic confirmation of EB subtype",
          "limited dermatology specialist centres"
        ],
        "country": "Argentina",
        "region": "South America"
      }
    },
    {
      "doc_id": "16_pku_turkey.pdf",
      "disease": "Phenylketonuria",
      "country": "Turkey",
      "study_design": {
        "phase": "2",
        "design_type": "parallel",
        "blinding": "open-label",
        "randomization_ratio": "2:1",
        "sample_size": null,
        "actual_enrollment": 102,
        "duration_months": 12,
        "treatment_arms": [
          {
            "name": "Pegvaliase",
            "n": 68,
            "dose": "escalating to 20 mg daily",
            "frequency": "daily",
            "route": "subcutaneous"
          },
          {
            "name": "Diet alone",
            "n": 34
          }
        ],
        "control_type": "no_treatment",
        "setting": "multi-centre",
        "sites_total": 24,
        "countries_total": 5
      },
      "eligibility_inclusion": [
        {
          "text": "Age 18 to 55 years",
          "category": "age"
        },
        {
          "text": "Confirmed PKU: documented PAH gene mutations or newborn screening diagnosis with historical Phe > 1000 micromol/L",
          "category": "disease_definition"
        },
        {
          "text": "Blood Phe >= 600 micromol/L at screening (mean of 2 measurements)",
          "category": "lab_value"
        },
        {
          "text": "Willing to maintain current dietary regimen",
          "category": "compliance"
        },
        {
          "text": "Effective contraception for women of childbearing potential",
          "category": "pregnancy"
        }
      ],
      "eligibility_exclusion": [
        {
          "text": "Current pregnancy or breastfeeding or planned pregnancy",
          "category": "pregnancy"
        },
        {
          "text": "History of anaphylaxis to PEGylated therapies",
          "category": "medical_history"
        },
        {
          "text": "Known hypersensitivity to pegvaliase",
          "category": "allergy"
        },
        {
          "text": "Concurrent use of sapropterin (washout >= 14 days)",
          "category": "washout"
        },
        {
          "text": "Significant immunodeficiency or autoimmune disorder",
          "category": "medical_history"
        },
        {
          "text": "Unable to self-inject or commit to daily injection",
          "category": "compliance"
        },
        {
          "text": "ALT > 2x ULN",
          "category": "organ_function"
        }
      ],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 4,200",
          "geography": "Turkey"
        },
        {
          "data_type": "population",
          "value": "approximately 20,000 diagnosed",
          "geography": "Turkey"
        },
        {
          "data_type": "incidence",
          "value": "1 in 4,500 live births",
          "geography": "Turkey"
        }
      ],
      "screening_flow": {
        "screened": 156,
        "screen_failures": 54,
        "randomized": 102,
        "treated": 98,
        "completed": 82,
        "discontinued": 20,
        "screen_failure_rate": 34.6,
        "screen_fail_reasons": [
          {
            "reason": "Blood Phe below 600 micromol/L",
            "count": 22,
            "percentage": 40.7
          },
          {
            "reason": "History of anaphylaxis to PEGylated therapies",
            "count": 8,
            "percentage": 14.8
          },
          {
            "reason": "Inability to self-inject or commit to schedule",
            "count": 8,
            "percentage": 14.8
          },
          {
            "reason": "Pregnancy or planned pregnancy",
            "count": 6,
            "percentage": 11.1
          },
          {
            "reason": "Abnormal immune function tests",
            "count": 5,
            "percentage": 9.3
          }
        ]
      },
      "operational_burden": {
        "visit_schedule": {
          "total_visits": 17,
          "frequency": "screening, baseline, Wk1,2,4,6,8,10,12,16,20,24,32,40,48,52"
        },
        "central_lab_required": true,
        "central_lab_analytes": [
          "blood Phe (tandem MS)",
          "CBC",
          "liver function",
          "anti-pegvaliase antibodies (IgG,IgM,IgE)",
          "complement levels",
          "tryptase"
        ],
        "hard_gates": [
          "blood Phe threshold",
          "self-injection ability",
          "epinephrine auto-injector carriage",
          "anaphylaxis management plan"
        ]
      },
      "endpoints": [
        {
          "type": "primary",
          "name": "Change in blood Phe concentration",
          "timepoint": "Week 48"
        },
        {
          "type": "secondary",
          "name": "Proportion achieving Phe < 360 micromol/L",
          "timepoint": "Week 48"
        },
        {
          "type": "secondary",
          "name": "ADHD-RS score change"
        },
        {
          "type": "secondary",
          "name": "PKU-QoL change"
        },
        {
          "type": "safety",
          "name": "Injection site reactions, anaphylaxis, arthralgia, anti-drug antibodies, liver function"
        }
      ],
      "sites_and_investigators": {
        "total_sites": 24,
        "total_countries": 5,
        "countries": [
          "Turkey",
          "Germany",
          "United States",
          "United Kingdom",
          "Italy"
        ],
        "country_enrollment": [
          {
            "country": "Turkey",
            "n": 48,
            "percentage": 47.1
          },
          {
            "country": "Germany",
            "n": 20,
            "percentage": 19.6
          },
          {
            "country": "United States",
            "n": 16,
            "percentage": 15.7
          },
          {
            "country": "United Kingdom",
            "n": 10,
            "percentage": 9.8
          },
          {
            "country": "Italy",
            "n": 8,
            "percentage": 7.8
          }
        ]
      },
      "local_guidelines": {
        "guideline_name": "Turkish Ministry of Health National PKU Guidelines 2023",
        "key_recommendations": [
          "Lifelong dietary Phe restriction",
          "Target Phe 120-360 micromol/L all ages",
          "Sapropterin trial for all newly diagnosed",
          "Monthly blood Phe monitoring (children), every 3 months (adults)",
          "Neuropsychological assessment every 2 years"
        ],
        "impact_on_feasibility": "One of highest PKU prevalence globally (1:4,200) due to consanguinity; national NBS since 1993 with >99% coverage; 42 metabolic centres; 12,500 patients in registry"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 20000,
        "registry_name": "Turkish PKU Registry",
        "registry_size": 12500,
        "adults_registered": 8200,
        "phe_above_600": 5300,
        "estimated_eligible": 3200,
        "diagnostic_delay_years": null
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 0.1,
          "diagnostic_tests_required": [
            "newborn screening (Guthrie test)",
            "plasma phenylalanine levels",
            "PAH gene sequencing"
          ],
          "specialist_type": "metabolic disease specialist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Phenylalanine-restricted diet",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Low-phenylalanine diet + amino acid supplements"
            },
            {
              "line": 2,
              "therapy": "Sapropterin (BH4) for responsive patients"
            }
          ]
        },
        "trial_phases": [
          {
            "phase": "screening",
            "duration": "2 weeks",
            "visits": 2,
            "procedures": [
              "Phe level monitoring",
              "dietary assessment"
            ]
          },
          {
            "phase": "treatment",
            "duration": "24 weeks",
            "visits": 6,
            "visit_frequency": "monthly"
          }
        ],
        "participation_barriers": [
          "dietary compliance requirement",
          "Phe level threshold for eligibility",
          "PAH genotype restriction"
        ],
        "country": "Turkey",
        "region": "Middle East"
      }
    },
    {
      "doc_id": "17_pompe_disease_india.pdf",
      "disease": "Pompe Disease",
      "country": "India",
      "study_design": null,
      "eligibility_inclusion": [],
      "eligibility_exclusion": [],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 40,000",
          "geography": "India"
        },
        {
          "data_type": "population",
          "value": "approximately 35,000 affected, only 1,200 diagnosed",
          "geography": "India"
        }
      ],
      "screening_flow": {
        "screen_failure_rate_avg": "40-50%"
      },
      "operational_burden": null,
      "endpoints": [],
      "sites_and_investigators": {
        "investigator_count": 18,
        "centres": 12,
        "pi_experienced": 8
      },
      "local_guidelines": {
        "guideline_name": "Indian Academy of Medical Genetics Pompe Disease Guidelines 2024",
        "key_recommendations": [
          "Alglucosidase alfa 20 mg/kg IV every 2 weeks",
          "ERT as early as possible for IOPD",
          "Avalglucosidase alfa approved 2024",
          "FVC monitoring every 3-6 months",
          "Newborn screening expansion planned by 2028"
        ],
        "impact_on_feasibility": "Only 3.4% diagnostic rate; ERT access through Sanofi humanitarian program (180 patients); pilot NBS in 3 states covering 15% of births; CDSCO approval 3-6 months; mandatory post-trial access provisions"
      },
      "patient_population": {
        "estimated_affected": 35000,
        "estimated_diagnosed": 1200,
        "registry_name": "Indian Pompe Disease Registry (NIRRCH)",
        "registry_size": 680,
        "on_ert": 180,
        "symptomatic_untreated": 480,
        "lopd_confirmed": 540,
        "estimated_eligible_ert_switch": 80,
        "estimated_eligible_naive": 120,
        "diagnostic_delay_iopd_months": 3.2,
        "diagnostic_delay_lopd_years": 8.6,
        "referral_centres": 28
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 7.5,
          "diagnostic_tests_required": [
            "GAA enzyme assay",
            "GAA gene sequencing",
            "muscle biopsy"
          ],
          "specialist_type": "neurologist or metabolic specialist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "ERT with alglucosidase alfa",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Alglucosidase alfa IV every 2 weeks"
            },
            {
              "line": 2,
              "therapy": "Avalglucosidase alfa (next-gen ERT)"
            }
          ]
        },
        "participation_barriers": [
          "ERT access limitations in rural India",
          "diagnostic delay due to low awareness",
          "newborn screening not universal"
        ],
        "country": "India",
        "region": "Asia-Pacific"
      }
    },
    {
      "doc_id": "18_pnh_sweden.pdf",
      "disease": "Paroxysmal Nocturnal Hemoglobinuria",
      "country": "Sweden",
      "study_design": {
        "phase": "3",
        "design_type": "parallel",
        "blinding": "double-blind",
        "randomization_ratio": "1:1",
        "sample_size": null,
        "actual_enrollment": 150,
        "duration_months": 6,
        "treatment_arms": [
          {
            "name": "Iptacopan + eculizumab",
            "n": 75,
            "dose": "200 mg twice daily",
            "route": "oral"
          },
          {
            "name": "Placebo + eculizumab",
            "n": 75
          }
        ],
        "control_type": "placebo",
        "setting": "multi-centre",
        "sites_total": 48,
        "countries_total": 10
      },
      "eligibility_inclusion": [
        {
          "text": "Age 18 to 75 years",
          "category": "age"
        },
        {
          "text": "PNH confirmed by flow cytometry: GPI-deficient granulocyte clone >= 10%",
          "category": "biomarker"
        },
        {
          "text": "Hemoglobin < 10 g/dL at screening",
          "category": "lab_value"
        },
        {
          "text": "Stable eculizumab for >= 6 months",
          "category": "prior_therapy"
        },
        {
          "text": "LDH < 1.5x ULN",
          "category": "lab_value"
        },
        {
          "text": "Reticulocyte count > ULN",
          "category": "lab_value"
        },
        {
          "text": "Meningococcal vaccination current",
          "category": "vaccination"
        }
      ],
      "eligibility_exclusion": [
        {
          "text": "Active or recent Neisseria meningitidis infection",
          "category": "infection"
        },
        {
          "text": "Active thrombosis or anticoagulation change within 3 months",
          "category": "medical_history"
        },
        {
          "text": "Bone marrow failure requiring >= 4 RBC transfusions in 12 weeks",
          "category": "disease_severity"
        },
        {
          "text": "Prior complement inhibitor other than eculizumab",
          "category": "prior_therapy"
        },
        {
          "text": "History of bone marrow transplantation",
          "category": "medical_history"
        },
        {
          "text": "eGFR < 30",
          "category": "organ_function"
        }
      ],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "13 per million",
          "geography": "Sweden"
        },
        {
          "data_type": "population",
          "value": "approximately 135 diagnosed patients",
          "geography": "Sweden"
        },
        {
          "data_type": "incidence",
          "value": "1.3 per million per year",
          "geography": "Sweden"
        }
      ],
      "screening_flow": {
        "screened": 218,
        "screen_failures": 68,
        "randomized": 150,
        "treated": 148,
        "completed": 138,
        "discontinued": 12,
        "screen_failure_rate": 31.2,
        "screen_fail_reasons": [
          {
            "reason": "Hemoglobin >= 10 g/dL at screening",
            "count": 28,
            "percentage": 41.2
          },
          {
            "reason": "GPI-deficient clone < 10%",
            "count": 12,
            "percentage": 17.6
          },
          {
            "reason": "Eculizumab not stable for 6 months",
            "count": 10,
            "percentage": 14.7
          },
          {
            "reason": "Active thrombosis or anticoagulation change",
            "count": 8,
            "percentage": 11.8
          },
          {
            "reason": "Withdrawal of consent",
            "count": 6,
            "percentage": 8.8
          },
          {
            "reason": "Other (renal impairment, infection)",
            "count": 4,
            "percentage": 5.9
          }
        ]
      },
      "operational_burden": {
        "vaccination_requirements": [
          {
            "vaccine_type": "meningococcal",
            "requirement_type": "required",
            "timing": "current per local guidelines, booster every 3 years"
          }
        ],
        "visit_schedule": {
          "total_visits": 18,
          "frequency": "eculizumab infusions every 2 weeks plus assessment visits"
        },
        "central_lab_required": true,
        "central_lab_analytes": [
          "CBC with reticulocyte count",
          "LDH",
          "indirect bilirubin",
          "haptoglobin",
          "free hemoglobin",
          "complement CH50",
          "C3d on erythrocytes",
          "liver function",
          "iptacopan drug levels"
        ],
        "hard_gates": [
          "GPI-deficient clone >= 10%",
          "stable eculizumab",
          "meningococcal vaccination",
          "prophylactic antibiotics"
        ]
      },
      "endpoints": [
        {
          "type": "primary",
          "name": "Change in hemoglobin",
          "timepoint": "Week 24"
        },
        {
          "type": "secondary",
          "name": "Proportion achieving hemoglobin >= 12 g/dL",
          "timepoint": "Week 24"
        },
        {
          "type": "secondary",
          "name": "Change in reticulocyte count"
        },
        {
          "type": "secondary",
          "name": "Transfusion avoidance rate"
        },
        {
          "type": "secondary",
          "name": "FACIT-Fatigue score change"
        },
        {
          "type": "safety",
          "name": "Breakthrough hemolysis, Neisseria surveillance, hepatic function"
        }
      ],
      "sites_and_investigators": {
        "total_sites": 48,
        "total_countries": 10,
        "countries": [
          "Sweden",
          "Denmark",
          "Norway",
          "Finland",
          "Germany",
          "France",
          "United Kingdom",
          "United States",
          "Japan",
          "Australia"
        ],
        "investigator_requirements": "hematologist with >= 2 years PNH experience, eculizumab infusion capability, high-sensitivity flow cytometry access",
        "country_enrollment": [
          {
            "country": "Sweden",
            "n": 18,
            "percentage": 12.0
          },
          {
            "country": "Denmark",
            "n": 12,
            "percentage": 8.0
          },
          {
            "country": "Norway",
            "n": 8,
            "percentage": 5.3
          },
          {
            "country": "Finland",
            "n": 6,
            "percentage": 4.0
          },
          {
            "country": "Germany",
            "n": 28,
            "percentage": 18.7
          },
          {
            "country": "France",
            "n": 22,
            "percentage": 14.7
          },
          {
            "country": "United Kingdom",
            "n": 18,
            "percentage": 12.0
          },
          {
            "country": "United States",
            "n": 24,
            "percentage": 16.0
          },
          {
            "country": "Japan",
            "n": 10,
            "percentage": 6.7
          },
          {
            "country": "Australia",
            "n": 4,
            "percentage": 2.7
          }
        ]
      },
      "local_guidelines": {
        "guideline_name": "Swedish Society of Hematology PNH Guidelines 2023",
        "key_recommendations": [
          "Complement inhibitor for symptomatic intravascular hemolysis",
          "Meningococcal vaccination mandatory with 3-year booster",
          "Blood monitoring every 4 weeks on eculizumab",
          "High-sensitivity flow cytometry at diagnosis and annually"
        ],
        "impact_on_feasibility": "Centralized care in 7 university hospitals; Swedish PNH Registry (98 patients); Nordic countries collectively contributed 29.3% enrollment"
      },
      "patient_population": {
        "estimated_diagnosed_patients": 135,
        "registry_name": "Swedish PNH Registry",
        "registry_size": 98,
        "on_eculizumab": 82,
        "hb_below_10": 48,
        "estimated_eligible": 32,
        "referral_centres": 7
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 2.5,
          "diagnostic_tests_required": [
            "flow cytometry for GPI-anchored proteins",
            "LDH levels",
            "reticulocyte count"
          ],
          "specialist_type": "hematologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "Complement C5 inhibition with eculizumab",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Eculizumab IV every 2 weeks"
            },
            {
              "line": 2,
              "therapy": "Ravulizumab (long-acting C5 inhibitor)"
            }
          ]
        },
        "trial_phases": [
          {
            "phase": "screening",
            "duration": "4 weeks",
            "visits": 3,
            "procedures": [
              "flow cytometry",
              "LDH",
              "blood draw"
            ]
          },
          {
            "phase": "treatment",
            "duration": "26 weeks",
            "visits": 14,
            "visit_frequency": "every 2 weeks"
          }
        ],
        "participation_barriers": [
          "meningococcal vaccination requirement",
          "LDH threshold for eligibility",
          "complement inhibitor washout period"
        ],
        "country": "Sweden",
        "region": "Europe"
      }
    },
    {
      "doc_id": "19_tsc_mexico.pdf",
      "disease": "Tuberous Sclerosis Complex",
      "country": "Mexico",
      "study_design": null,
      "eligibility_inclusion": [],
      "eligibility_exclusion": [],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 15,000",
          "geography": "Mexico"
        },
        {
          "data_type": "population",
          "value": "approximately 8,500 affected, 2,800 diagnosed",
          "geography": "Mexico"
        },
        {
          "data_type": "incidence",
          "value": "1 in 6,000 to 1 in 10,000 live births",
          "geography": "Mexico"
        }
      ],
      "screening_flow": {
        "screen_failure_rate_avg": "35-45%",
        "screening_to_randomization_ratio": "3.0:1"
      },
      "operational_burden": null,
      "endpoints": [],
      "sites_and_investigators": {
        "investigator_count": 16,
        "centres": 10,
        "pi_experienced": 3
      },
      "local_guidelines": {
        "guideline_name": "Mexican Academy of Neurology TSC Guidelines 2024",
        "key_recommendations": [
          "Vigabatrin first-line for infantile spasms",
          "Everolimus for SEGA >= 1 cm, AML >= 3 cm, refractory epilepsy",
          "Brain MRI every 1-3 years until age 25",
          "Renal MRI every 1-3 years lifelong",
          "TAND screening annually"
        ],
        "impact_on_feasibility": "22 centres in registry but 32% patients in Mexico City; everolimus supply interruptions in 35% of centres; genetic testing at INMEGEN (6-12 weeks); COFEPRIS approval 4-6 months"
      },
      "patient_population": {
        "estimated_affected": 8500,
        "estimated_diagnosed": 2800,
        "registry_name": "Mexican TSC Registry (Registro Mexicano de Esclerosis Tuberosa)",
        "registry_size": 1600,
        "with_epilepsy": 1200,
        "with_aml_3cm": 640,
        "on_everolimus": 600,
        "estimated_eligible_epilepsy_trial": 200,
        "estimated_eligible_mtor_trial": 250,
        "referral_centres": 22
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 3.0,
          "diagnostic_tests_required": [
            "clinical criteria (Tuberous Sclerosis Diagnostic Criteria)",
            "MRI brain",
            "genetic testing for TSC1/TSC2"
          ],
          "specialist_type": "neurologist or geneticist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "mTOR inhibitor (everolimus) for SEGA and renal angiomyolipomas",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Everolimus for SEGA/renal AML"
            },
            {
              "line": 2,
              "therapy": "Vigabatrin for infantile spasms"
            }
          ]
        },
        "participation_barriers": [
          "multi-organ involvement complicates eligibility",
          "epilepsy monitoring requirements",
          "limited mTOR inhibitor access"
        ],
        "country": "Mexico",
        "region": "North America"
      }
    },
    {
      "doc_id": "20_attr_amyloidosis_portugal.pdf",
      "disease": "Hereditary Transthyretin Amyloidosis",
      "country": "Portugal",
      "study_design": {
        "phase": "3",
        "design_type": "parallel",
        "blinding": "double-blind",
        "randomization_ratio": "2:1",
        "sample_size": null,
        "actual_enrollment": 192,
        "duration_months": 18,
        "treatment_arms": [
          {
            "name": "Acoramidis",
            "n": 128,
            "dose": "800 mg twice daily",
            "route": "oral"
          },
          {
            "name": "Placebo",
            "n": 64
          }
        ],
        "control_type": "placebo",
        "setting": "multi-centre",
        "sites_total": 38,
        "countries_total": 9
      },
      "eligibility_inclusion": [
        {
          "text": "Age 18 to 80 years",
          "category": "age"
        },
        {
          "text": "Documented pathogenic TTR variant confirmed by central lab",
          "category": "biomarker"
        },
        {
          "text": "Amyloid deposition confirmed by tissue biopsy or Tc-99m pyrophosphate scintigraphy (Perugini >= 2)",
          "category": "disease_definition"
        },
        {
          "text": "PND score I, II, IIIa, or IIIb (FAP stage 1 or 2)",
          "category": "disease_severity"
        },
        {
          "text": "NIS >= 5 and <= 130",
          "category": "disease_severity"
        },
        {
          "text": "If on tafamidis, stable dose >= 6 months",
          "category": "prior_therapy"
        }
      ],
      "eligibility_exclusion": [
        {
          "text": "PND score IV (wheelchair-bound or bedridden, FAP stage 3)",
          "category": "disease_severity"
        },
        {
          "text": "Prior liver transplantation",
          "category": "medical_history"
        },
        {
          "text": "Current or prior gene silencing therapy within 6 months",
          "category": "washout"
        },
        {
          "text": "LVEF < 40%, NT-proBNP > 3000 pg/mL, NYHA class IV",
          "category": "cardiac"
        },
        {
          "text": "eGFR < 30",
          "category": "organ_function"
        },
        {
          "text": "Sensorimotor polyneuropathy from other causes",
          "category": "disease_definition"
        }
      ],
      "epidemiology": [
        {
          "data_type": "prevalence",
          "value": "1 in 538 in endemic regions (Póvoa de Varzim/Vila do Conde)",
          "geography": "Portugal (endemic)"
        },
        {
          "data_type": "population",
          "value": "3,200 symptomatic patients, 10,000 asymptomatic carriers",
          "geography": "Portugal"
        }
      ],
      "screening_flow": {
        "screened": 280,
        "screen_failures": 88,
        "randomized": 192,
        "treated": 188,
        "completed": 172,
        "discontinued": 20,
        "screen_failure_rate": 31.4,
        "screen_fail_reasons": [
          {
            "reason": "Polyneuropathy not attributable to ATTRv",
            "count": 26,
            "percentage": 29.5
          },
          {
            "reason": "Polyneuropathy stage 3 (PND IV)",
            "count": 18,
            "percentage": 20.5
          },
          {
            "reason": "TTR variant classified as VUS on central review",
            "count": 14,
            "percentage": 15.9
          },
          {
            "reason": "LVEF < 40%",
            "count": 12,
            "percentage": 13.6
          },
          {
            "reason": "Withdrawal of consent",
            "count": 10,
            "percentage": 11.4
          },
          {
            "reason": "NIS outside range",
            "count": 8,
            "percentage": 9.1
          }
        ]
      },
      "operational_burden": {
        "invasive_procedures": [
          {
            "name": "tissue biopsy or nuclear scintigraphy",
            "timing": [
              "screening"
            ],
            "purpose": "diagnosis_confirmation",
            "is_eligibility_requirement": true
          }
        ],
        "visit_schedule": {
          "total_visits": 14,
          "frequency": "screening (2), baseline, Mo1,2,3,6,9,12,15,18,19"
        },
        "central_lab_required": true,
        "central_lab_analytes": [
          "TTR levels",
          "prealbumin",
          "NT-proBNP",
          "troponin I",
          "CBC",
          "liver function",
          "renal function",
          "albumin",
          "retinol-binding protein"
        ],
        "hard_gates": [
          "pathogenic TTR variant confirmation",
          "amyloid tissue confirmation",
          "mNIS+7 certified assessors",
          "nerve conduction studies"
        ]
      },
      "endpoints": [
        {
          "type": "primary",
          "name": "Change in mNIS+7",
          "timepoint": "Month 18"
        },
        {
          "type": "secondary",
          "name": "Norfolk QoL-DN score change"
        },
        {
          "type": "secondary",
          "name": "10-meter walk test speed change"
        },
        {
          "type": "secondary",
          "name": "Grip strength change"
        },
        {
          "type": "secondary",
          "name": "Modified BMI (mBMI)"
        },
        {
          "type": "secondary",
          "name": "NT-proBNP change"
        },
        {
          "type": "secondary",
          "name": "Global longitudinal strain by echo"
        },
        {
          "type": "safety",
          "name": "Cardiac monitoring, hepatic function"
        }
      ],
      "sites_and_investigators": {
        "total_sites": 38,
        "total_countries": 9,
        "countries": [
          "Portugal",
          "France",
          "Sweden",
          "Japan",
          "Brazil",
          "United States",
          "Italy",
          "Spain",
          "Germany"
        ],
        "investigator_requirements": "neurologist with neuromuscular experience, certified NCS capability, echocardiography with strain imaging, patient panel >= 10 ATTRv",
        "country_enrollment": [
          {
            "country": "Portugal",
            "n": 52,
            "percentage": 27.1
          },
          {
            "country": "France",
            "n": 28,
            "percentage": 14.6
          },
          {
            "country": "Japan",
            "n": 26,
            "percentage": 13.5
          },
          {
            "country": "Sweden",
            "n": 22,
            "percentage": 11.5
          },
          {
            "country": "Brazil",
            "n": 20,
            "percentage": 10.4
          },
          {
            "country": "United States",
            "n": 18,
            "percentage": 9.4
          },
          {
            "country": "Italy",
            "n": 12,
            "percentage": 6.3
          },
          {
            "country": "Spain",
            "n": 8,
            "percentage": 4.2
          },
          {
            "country": "Germany",
            "n": 6,
            "percentage": 3.1
          }
        ]
      },
      "local_guidelines": {
        "guideline_name": "Sociedade Portuguesa de Neurologia ATTRv Guidelines 2023",
        "key_recommendations": [
          "Genetic testing for all first-degree relatives starting age 18",
          "Annual neurological, cardiac, and ophthalmologic monitoring for carriers",
          "Treatment at symptom onset: tafamidis, patisiran, inotersen, vutrisiran",
          "Liver transplant largely superseded by pharmacotherapy since 2012"
        ],
        "impact_on_feasibility": "World's oldest ATTRv registry (since 1939, 5,400 individuals); Unidade Corino de Andrade global reference centre; 80+ years clinical experience; highest global prevalence in endemic regions"
      },
      "patient_population": {
        "estimated_symptomatic": 3200,
        "asymptomatic_carriers": 10000,
        "with_polyneuropathy": 2400,
        "stage_1_2": 1600,
        "estimated_eligible": 1100,
        "registry_name": "Portuguese Familial Amyloidosis Registry (Unidade Corino de Andrade)",
        "registry_size": 5400,
        "referral_centres": null
      },
      "patient_journey": {
        "diagnostic_pathway": {
          "diagnostic_delay_years": 4.0,
          "diagnostic_tests_required": [
            "TTR gene sequencing",
            "tissue biopsy with Congo red staining",
            "nerve conduction studies"
          ],
          "specialist_type": "neurologist or cardiologist"
        },
        "treatment_pathway": {
          "current_standard_of_care": "TTR stabilizer (tafamidis) or gene silencing (patisiran/inotersen)",
          "treatment_lines": [
            {
              "line": 1,
              "therapy": "Tafamidis 80 mg daily"
            },
            {
              "line": 2,
              "therapy": "Patisiran IV every 3 weeks or inotersen SC weekly"
            }
          ]
        },
        "trial_phases": [
          {
            "phase": "screening",
            "duration": "4 weeks",
            "visits": 3,
            "procedures": [
              "nerve conduction study",
              "cardiac assessment",
              "blood draw"
            ]
          },
          {
            "phase": "treatment",
            "duration": "18 months",
            "visits": 9,
            "visit_frequency": "every 2 months"
          }
        ],
        "participation_barriers": [
          "neuropathy staging requirement",
          "cardiac involvement assessment",
          "TTR mutation confirmation"
        ],
        "country": "Portugal",
        "region": "Unknown"
      }
    }
  ]
}